Risk for Cannabis Use Disorder in People Who Use Cannabis to Cope with Internalizing Disorders: Implications for Policy and Practice

Abstract

The prevalence of Cannabis Use Disorder (CUD) is increasing in the United States, likely related to increasing cultural and legal acceptance of cannabis. While most cannabis users will not develop a CUD, certain behaviors may increase risk. For example, smoking to cope with anxiety or depressive disorders is associated with higher rates of cannabis use. Users who smoke to cope with these internalizing disorders (anxiety, depression) increase the addictive potential of cannabis. Systems that potentially maintain problematic use in people with internalizing disorders include the reward processing and the stress responsivity systems. Both exhibit neurobiological changes after chronic heavy cannabis use and are affected across internalizing disorders. The shared importance of these systems may warrant several recommendations for policy and practice. Some reexamine cannabis-related policy, invest in local communities, and improve cannabis education.

Keywords

cannabis cannabis use disorder internalizing disorders anxiety depression stress reward

Get full access to this article

View all access options for this article.

References

Acuff

S. F.

MacKillop

Murphy

J. G.

(2023). A contextualized reinforcer pathology approach to addiction. Nature Reviews Psychology, 2(5), Article 5. 309–323. https://doi.org/10.1038/s44159-023-00167-y

Alvidrez

Azocar

(1999). Distressed women’s clinic patients: Preferences for mental health treatments and perceived obstacles. General Hospital Psychiatry, 21(5), 340–347. https://doi.org/10.1016/S0163-8343(99)00038-9

American Psychiatric Association (2022). Diagnostic and statistical manual of mental disorders (5th ed. Text rev.).

Bovasso

G. B.

(2001). Cannabis abuse as a risk factor for depressive symptoms. American Journal of Psychiatry, 158(12), 2033–2037. https://doi.org/10.1176/appi.ajp.158.12.2033

Boyer

(2000). Do anxiety and depression have a common pathophysiological mechanism? Acta Psychiatrica Scandinavica, 102(s406), 24–29. https://doi.org/10.1111/j.0065-1591.2000.acp29-04.x

Bresin

Mekawi

(2019). Do marijuana use motives matter? Meta-analytic associations with marijuana use frequency and problems. Addictive Behaviors, 99, 106102. https://doi.org/10.1016/j.addbeh.2019.106102

Britannica ProCon.org. (2023). State-by-State Medical Marijuana Laws . Retrieved June 09, 2023, from https://medicalmarijuana.procon.org/legal-medical-marijuana-states-and-dc/

Cape

Whittington

Buszewicz

Wallace

Underwood

(2010). Brief psychological therapies for anxiety and depression in primary care: Meta-analysis and meta-regression. BMC Medicine, 8(1), 38. https://doi.org/10.1186/1741-7015-8-38

Castellanos-Ryan

Pingault

J. B.

Parent

Vitaro

Tremblay

R. E.

Seguin

J. R.

(2017). Adolescent cannabis use, change in neurocognitive function, and high-school graduation: A longitudinal study from early adolescence to young adulthood. Development and Psychopathology, 29(4), 1253–1266. https://doi.org/10.1017/S0954579416001280

10.

Collins

S. E.

(2016). Associations between socioeconomic factors and alcohol outcomes. Alcohol Research: Current Reviews, 38(1), 83–94.

11.

Cornelius

J. R.

Aizenstein

H. J.

Hariri

A. R.

(2010). Amygdala reactivity is inversely related to level of cannabis use in individuals with comorbid cannabis dependence and major depression. Addictive Behaviors, 35(6), 644–646. https://doi.org/10.1016/j.addbeh.2010.02.004

12.

Cougle

J. R.

Hakes

J. K.

Macatee

R. J.

Zvolensky

M. J.

Chavarria

(2016). Probability and correlates of dependence among regular users of alcohol, nicotine, cannabis, and cocaine: Concurrent and prospective analyses of the national epidemiologic survey on alcohol and related conditions. The Journal of Clinical Psychiatry, 77(4), e444–e450. https://doi.org/10.4088/JCP.14m09469

13.

Cuttler

Spradlin

Nusbaum

A. T.

Whitney

Hinson

J. M.

McLaughlin

R. J.

(2017). Blunted stress reactivity in chronic cannabis users. Psychopharmacology, 234, 2299–2309. https://doi.org/10.1007/s00213-017-4648-z

14.

Danielsson

A. K.

Lundin

Agardh

Allebeck

Forsell

(2016). Cannabis use, depression and anxiety: A 3-year prospective population-based study. Journal of Affective Disorders, 193, 103–108. https://doi.org/10.1016/j.jad.2015.12.045

15.

Degenhardt

Hall

Lynskey

(2001). The relationship between cannabis use, depression and anxiety among Australian adults: Findings from the national survey of mental health and well-being. Social Psychiatry and Psychiatric Epidemiology, 36, 219–227. https://doi.org/10.1007/s001270170052

16.

De la Peña-Arteaga

Fernández-Rodríguez

Moreira

P. S.

Abreu

Portugal-Nunes

Soriano-Mas

Morgado

(2022). An fMRI study of cognitive regulation of reward processing in generalized anxiety disorder (GAD). Psychiatry Research: Neuroimaging, 324, 111493. https://doi.org/10.1016/j.pscychresns.2022.111493

17.

Diehl

Honberg

Kimball

Douglas

(2017). The Doctor is Out: Continuing Disparities in Access to Mental and Physical Health Care . National Alliance on Mental Illness (NAMI). https://www.nami.org/Support-Education/Publications-Reports/Public-Policy-Reports/The-Doctor-is-Out/DoctorIsOut

18.

Feingold

Weiser

Rehm

Lev-Ran

(2015). The association between cannabis use and mood disorders: A longitudinal study. Journal of Affective Disorders, 172, 211–218. https://doi.org/10.1016/j.jad.2014.10.006

19.

Feingold

Weiser

Rehm

Lev-Ran

(2016). The association between cannabis use and anxiety disorders: Results from a population-based representative sample. European Neuropsychopharmacology, 26(3), 493–505. https://doi.org/10.1016/j.euroneuro.2015.12.037

20.

Fergusson

D. M.

Lynskey

M. T.

Horwood

L. J.

(1996). The short-term consequences of early onset cannabis use. Journal of Abnormal Child Psychology, 24(4), 499–512. https://doi.org/10.1007/BF01441571

21.

Firth

C. L.

Maher

J. E.

Dilley

J. A.

Darnell

Lovrich

N. P.

(2019). Did marijuana legalization in Washington state reduce racial disparities in adult marijuana arrests? Substance Use & Misuse, 54(9), 1582–1587. https://doi.org/10.1080/10826084.2019.1593007

22.

Glodosky

N. C.

Cuttler

(2020). Motives matter: Cannabis use motives moderate the associations between stress and negative affect. Addictive Behaviors, 102, 106188. https://doi.org/10.1016/j.addbeh.2019.106188

23.

Grant

B. F.

Stinson

F. S.

Dawson

D. A.

Chou

S. P.

Dufour

M. C.

Compton

Kaplan

(2004). Prevalence and co-occurrence of substance use disorders and independent mood and anxiety disorders: Results from the national epidemiologic survey on alcohol and related conditions. Archives of General Psychiatry, 61(8), 807–816. https://doi.org/10.1001/archpsyc.61.8.807

24.

Huang

Y. X.

Luo

Y. J.

(2010). Anxiety and feedback negativity. Psychophysiology, 47(5), 961–967. https://doi.org/10.1111/j.1469-8986.2010.00997.x

25.

Hasin

D. S.

Kerridge

B. T.

Saha

T. D.

Huang

Pickering

Smith

S. M.

Jung

Zhang

Grant

B. F.

(2016). Prevalence and correlates of DSM-5 Cannabis use disorder, 2012–2013: Findings from the national epidemiologic survey on alcohol and related conditions – III. The American Journal of Psychiatry, 173(6), 588–599. https://doi.org/10.1176/appi.ajp.2015.15070907

26.

Hasin

D. S.

Walsh

(2021). Trends over time in adult cannabis use: A review of recent findings. Current Opinion in Psychology, 38, 80–85. https://doi.org/10.1016/j.copsyc.2021.03.005

27.

Hathaway

A. D.

(2003). Cannabis effects and dependency concerns in long-term frequent users: A missing piece of the public health puzzle. Addiction Research & Theory, 11(6), 441–458. https://doi.org/10.1080/1606635021000041807

28.

Health Quality Ontario (2019). Internet-Delivered cognitive behavioural therapy for Major depression and anxiety disorders: A health technology assessment. Ontario Health Technology Assessment Series, 19(6), 1–199.

29.

(2018). Neural activity to threat in ventromedial prefrontal cortex correlates with individual differences in anxiety and reward processing. Neuropsychologia, 117, 566–573. https://doi.org/10.1016/j.neuropsychologia.2018.07.004

30.

Huys

Q. J.

Pizzagalli

D. A.

Bogdan

Dayan

(2013). Mapping anhedonia onto reinforcement learning: A behavioural meta-analysis. Biology of Mood & Anxiety Disorders, 3(1), 1–16. https://doi.org/10.1186/2045-5380-3-1

31.

Jefsen

O. H.

Erlangsen

Nordentoft

Hjorthøj

(2023). Cannabis use disorder and subsequent risk of psychotic and nonpsychotic unipolar depression and bipolar disorder. JAMA Psychiatry, 80(8), 803–810. https://doi.org/10.1001/jamapsychiatry.2023.1256

32.

Kedzior

K. K.

Laeber

L. T.

(2014). A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population-a meta-analysis of 31 studies. BMC Psychiatry, 14(1), 1–22. https://doi.org/10.1186/1471-244X-14-136

33.

Khalsa

J. H.

Bunt

Blum

Maggirwar

S. B.

Galanter

Potenza

M. N.

(2022). Review: Cannabinoids as medicinals. Current Addiction Reports, 9(4), 630–646. https://doi.org/10.1007/s40429-022-00438-3

34.

Khantzian

E. J.

(1997). The self-medication hypothesis of substance use disorders: A reconsideration and recent applications. Harvard Review of Psychiatry, 4(5), 231–244. https://doi.org/10.3109/10673229709030550

35.

Kondrad

Reid

(2013). Colorado Family Physicians’ attitudes toward medical marijuana. The Journal of the American Board of Family Medicine, 26(1), 52–60. https://doi.org/10.3122/jabfm.2013.01.120089

36.

Koob

G. F.

(2013). Addiction is a reward deficit and stress surfeit disorder. Frontiers in Psychiatry, 4, 72. https://doi.org/10.3389/fpsyt.2013.00072

37.

Koob

G. F.

Caine

S. B.

Hyytia

Markou

Parsons

L. H.

Roberts

A. J.

Weiss

(1999). Neurobiology of drug addiction. In Glantz

M. D.

Hartel

C. R.

(Eds.), Drug abuse: Origins & interventions (pp. 161–190). American Psychological Association.

38.

Koob

G. F.

Le Moal

(2001). Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology, 24(2), 97–129. https://doi.org/10.1016/S0893-133X(00)00195-0

39.

Koob

G. F.

Volkow

N. D.

(2010). Neurocircuitry of addiction. Neuropsychopharmacology, 35(1), 217–238. https://doi.org/10.1038/npp.2009.110

40.

Lac

Luk

J. W.

(2018). Testing the amotivational syndrome: Marijuana use longitudinally predicts lower self-efficacy even after controlling for demographics, personality, and alcohol and cigarette use. Prevention Science, 19(2), 117–126. https://doi.org/10.1007/s11121-017-0811-3

41.

Leventhal

A. M.

Bello

M. S.

Unger

J. B.

Strong

D. R.

Kirkpatrick

M. G.

Audrain-McGovern

(2015). Diminished alternative reinforcement as a mechanism underlying socioeconomic disparities in adolescent substance use. Preventive Medicine, 80, 75–81. https://doi.org/10.1016/j.ypmed.2015.05.021

42.

Lev-Ran

Roerecke

Le Foll

George

T. P.

McKenzie

Rehm

(2014). The association between cannabis use and depression: A systematic review and meta-analysis of longitudinal studies. Psychological Medicine, 44(4), 797–810. https://doi.org/10.1017/S0033291713001438

43.

Lowe

D. J.

Sasiadek

J. D.

Coles

A. S.

George

T. P.

(2019). Cannabis and mental illness: A review. European Archives of Psychiatry and Clinical Neuroscience, 269(1), 107–120. https://doi.org/10.1007/s00406-018-0970-7

44.

Luijten

Schellekens

A. F.

Kühn

Machielse

M. W.

Sescousse

(2017). Disruption of reward processing in addiction: An image-based meta-analysis of functional magnetic resonance imaging studies. JAMA Psychiatry, 74(4), 387–398. https://doi.org/10.1001/jamapsychiatry.2016.3084

45.

Martin

E. I.

Ressler

K. J.

Binder

Nemeroff

C. B.

(2009). The neurobiology of anxiety disorders: Brain imaging, genetics, and psychoneuroendocrinology. Psychiatric Clinics, 32(3), 549–575. https://doi.org/10.1016/j.psc.2009.05.004

46.

Martz

M. E.

Trucco

E. M.

Cope

L. M.

Hardee

J. E.

Jester

J. M.

Zucker

R. A.

Heitzeg

M. M.

(2016). Association of marijuana use with blunted nucleus accumbens response to reward anticipation. JAMA Psychiatry, 73(8), 838–844. https://doi.org/10.1001/jamapsychiatry.2016.1161

47.

McEwen

B. S.

(1998). Stress, adaptation, and disease: Allostasis and allostatic load. Annals of the New York Academy of Sciences, 840(1), 33–44. https://doi.org/10.1111/j.1749-6632.1998.tb09546.x

48.

McEwen

B. S.

(2003). Mood disorders and allostatic load. Biological Psychiatry, 54(3), 200–207. https://doi.org/10.1016/S0006-3223(03)00177-X

49.

McEwen

B. S.

(2004). Protection and damage from acute and chronic stress: Allostasis and allostatic overload and relevance to the pathophysiology of psychiatric disorders. Annals of the New York Academy of Sciences, 1032(1), 1–7. https://doi.org/10.1196/annals.1314.001

50.

Mohr

D. C.

Hart

S. L.

Howard

Julian

Vella

Catledge

Feldman

M. D.

(2006). Barriers to psychotherapy among depressed and nondepressed primary care patients. Annals of Behavioral Medicine, 32(3), 254–258. https://doi.org/10.1207/s15324796abm3203_12

51.

Moore

R. A.

Fisher

Finn

D. P.

Finnerup

N. B.

Gilron

Haroutounian

Eccleston

(2021). Cannabinoids, cannabis, and cannabis-based medicines for pain management: An overview of systematic reviews. Pain, 162(8), S67–S79. https://doi.org/10.1097/j.pain.0000000000002295

52.

National Conference of State Legislatures. (2023). State Medical Cannabis Laws . Retrieved June 09, 2023, from https://www.ncsl.org/health/state-medical-cannabis-laws#anchor8841

53.

Nelson

B. D.

Kessel

E. M.

Klein

D. N.

Shankman

S. A.

(2018). Depression symptom dimensions and asymmetrical frontal cortical activity while anticipating reward. Psychophysiology, 55(1), e12892. https://doi.org/10.1111/psyp.12892

54.

Nestler

E. J.

Barrot

DiLeone

R. J.

Eisch

A. J.

Gold

S. J.

Monteggia

L. M.

(2002). Neurobiology of depression. Neuron, 34(1), 13–25. https://doi.org/10.1016/S0896-6273(02)00653-0

55.

O'Grady

(2020). Cannabis research database shows how U.S. funding focuses on harms of the drug. Science. https://www.science.org/content/article/cannabis-research-database-shows-how-us-funding-focuses-harms-drug

56.

Onaemo

V. N.

Fawehinmi

T. O.

D’Arcy

(2021). Comorbid cannabis use disorder with major depression and generalized anxiety disorder: A systematic review with meta-analysis of nationally representative epidemiological surveys. Journal of Affective Disorders, 281, 467–475. https://doi.org/10.1016/j.jad.2020.12.043

57.

Pacheco-Colón

Limia

J. M.

Gonzalez

(2018). Nonacute effects of cannabis use on motivation and reward sensitivity in humans: A systematic review. Psychology of Addictive Behaviors, 32(5), 497. https://doi.org/10.1037/adb0000380

58.

Patton

G. C.

Coffey

Carlin

J. B.

Degenhardt

Lynskey

Hall

(2002). Cannabis use and mental health in young people: Cohort study. BMJ, 325(7374), 1195–1198. https://doi.org/10.1136/bmj.325.7374.1195

59.

Potenza

M. N.

Bunt

Khalsa

J. H.

(2023). Addiction medicine physicians and medicinal cannabinoids. JAMA Psychiatry, 80(7), 659–660. https://doi.org/10.1001/jamapsychiatry.2023.0731

60.

Schleider

J. L.

Weisz

J. R.

(2017). Little treatments, promising effects? Meta-analysis of single-session interventions for youth psychiatric problems. J. Am. Acad. Child Adolesc. Psyvhiatry, 56(2), 107–115. https://doi.org/10.1016/j.jaac.2016.11.007

61.

Sharpe

Sinclair

Kramer

de Manincor

Sarris

(2020). Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties. Journal of Translational Medicine, 18, 1–21. https://doi.org/10.1186/s12967-020-02518-2

62.

Simon

Shauna G

Jamner

Larry D.

Dent

Amy L

Granger

Douglas A.

Riis

Jenna L

(2023). Hypothalamic-pituitary-adrenal and sympathetic nervous system responses to social evaluative stress in chronic cannabis users and non-users. Addictive Behaviors, 136, 107489. http://dx.doi.org/10.1016/j.addbeh.2022.107489

63.

Skumlien

Langley

Lawn

Voon

Curran

H. V.

Roiser

J. P.

Sahakian

B. J.

(2021). The acute and non-acute effects of cannabis on reward processing: A systematic review. Neuroscience & Biobehavioral Reviews, 130, 512–528. https://doi.org/10.1016/j.neubiorev.2021.09.008

64.

Sofis

M. J.

Budney

A. J.

Stanger

Knapp

A. A.

Borodovsky

J. T.

(2020). Greater delay discounting and cannabis coping motives are associated with more frequent cannabis use in a large sample of adult cannabis users. Drug and Alcohol Dependence, 207, 107820. https://doi.org/10.1016/j.drugalcdep.2019.107820

65.

Somaini

Manfredini

Amore

Zaimovic

Raggi

M. A.

Leonardi

Gerra

(2012). Psychobiological responses to unpleasant emotions in cannabis users. European Archives of Psychiatry and Clinical Neuroscience, 262, 47–57. https://doi.org/10.1007/s00406-011-0223-5

66.

Substance Abuse and Mental Health Services Administration. (2022). Key substance use and mental health indicators in the United States : Results from the 2021 National Survey on Drug Use and Health (HHS Publication No. PEP22-07-01-005, NSDUH Series H-57). Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report

67.

Temple

E. C.

Driver

Brown

R. F.

(2014). Cannabis use and anxiety: Is stress the missing piece of the puzzle? Frontiers in Psychiatry, 5, 168. https://doi.org/10.3389/fpsyt.2014.00168

68.

Todd

(2018). The benefits of marijuana legalization and regulation “criminal justice at a crossroads” symposium. Berkeley Journal of Criminal Law, 23(1), 99–119. https://doi.org/10.15779/Z38NK3652D

69.

Treadway

M. T.

Bossaller

N. A.

Shelton

R. C.

Zald

D. H.

(2012). Effort-based decision-making in major depressive disorder: A translational model of motivational anhedonia. Journal of Abnormal Psychology, 121(3), 553. https://doi.org/10.1037/a0028813

70.

Turner

Mota

Bolton

Sareen

(2018). Self-medication with alcohol or drugs for mood and anxiety disorders: A narrative review of the epidemiological literature. Depression and Anxiety, 35(9), 851–860. https://doi.org/10.1002/da.22771

71.

Van Hell

H. H.

Vink

Ossewaarde

Jager

Kahn

R. S.

Ramsey

N. F.

(2010). Chronic effects of cannabis use on the human reward system: An fMRI study. European Neuropsychopharmacology, 20(3), 153–163. https://doi.org/10.1016/j.euroneuro.2009.11.010

72.

Van Laar

Van Dorsselaer

Monshouwer

De Graaf

(2007). Does cannabis use predict the first incidence of mood and anxiety disorders in the adult population? Addiction, 102(8), 1251–1260. https://doi.org/10.1111/j.1360-0443.2007.01875.x

73.

Vinkers

C. H.

Kuzminskaite

Lamers

Giltay

E. J.

Penninx

B. W.

(2021). An integrated approach to understand biological stress system dysregulation across depressive and anxiety disorders. Journal of Affective Disorders, 283, 139–146. https://doi.org/10.1016/j.jad.2021.01.051

74.

Wardenaar

K. J.

Vreeburg

S. A.

van Veen

Giltay

E. J.

Veen

Penninx

B. W.

Zitman

F. G.

(2011). Dimensions of depression and anxiety and the hypothalamo-pituitary-adrenal axis. Biological Psychiatry, 69(4), 366–373. https://doi.org/10.1016/j.biopsych.2010.09.005

75.

Weinberger

A. H.

Zhu

Levin

Barrington-Trimis

J. L.

Copeland

Wyka

Kim

J. H.

Goodwin

R. D.

(2020). Cannabis use among US adults with anxiety from 2008 to 2017: The role of state-level cannabis legalization. Drug and Alcohol Dependence, 214, 108163. https://doi.org/10.1016/j.drugalcdep.2020.108163

76.

Wolkowitz

O. M.

Epel

E. S.

Reus

V. I.

(2001). Stress hormone-related psychopathology: Pathophysiological and treatment implications. The World Journal of Biological Psychiatry, 2(3), 115–143. https://doi.org/10.3109/15622970109026799

77.

Young

A. S.

Klap

Sherbourne

C. D.

Wells

K. B.

(2001). The quality of care for depressive and anxiety disorders in the United States. Archives of General Psychiatry, 58(1), 55–61. https://doi.org/10.1001/archpsyc.58.1.55

78.

Zolotov

Metri

Calabria

Kogan

(2021). Medical cannabis education among healthcare trainees: A scoping review. Complementary Therapies in Medicine, 58, 102675. https://doi.org/10.1016/j.ctim.2021.102675